P&G said that Actonel (risedronate sodium tablets), a therapy proven to reduce the risk of both vertebral and nonvertebral fractures in postmenopausal women with osteoporosis, will soon be available in this monthly two-day dose option.
P&G said that in previous clinical trials of daily Actonel 5 mg, nonvertebral fracture reduction was demonstrated at a composite endpoint of six sites commonly associated with osteoporotic fractures – leg, humerus, hip, wrist, collarbone, and pelvis.